MétaCan
Menu
Back to cohort
Record W4402311649 · doi:10.1016/j.eururo.2024.08.021

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial

2024· article· en· W4402311649 on OpenAlexaff
Andrew J. Armstrong, Oliver Sartor, Johann S. de Bono, Kim Chi, Karim Fizazi, Bernd J. Krause, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Fred Saad, Tomasz M. Beer, Jiwen Wu, Osvaldo Mirante, Michael J. Morris

Bibliographic record

VenueEuropean Urology · 2024
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsUniversité de MontréalUniversity of British Columbia
FundersNational Cancer InstituteMedical Research CouncilNovartis Pharmaceuticals CorporationNovartis
KeywordsMedicineProstate cancerGlutamate carboxypeptidase IIOncologyProstateProstate-specific antigenInternal medicineAntigenCastrationClinical trialUrologyCancerImmunologyHormone

Abstract

fetched live from OpenAlex

Declining prostate-specific antigen levels during [ 177 Lu]Lu-PSMA-617 treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer were strongly associated with prolonged radiographic progression-free survival, overall survival, and time to health-related quality-of-life worsening. These findings demonstrate the prognostic importance of this biomarker in patients receiving PSMA-targeted radioligand therapy. The prognostic value of declining prostate-specific antigen (PSA) levels is under investigation in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) receiving PSMA-targeted radioligand therapy with [ 177 Lu]Lu-PSMA-617 ( 177 Lu-PSMA-617). This post hoc analysis of the phase 3 VISION trial aimed to evaluate associations between PSA decline and clinical and patient-reported outcomes in patients receiving 177 Lu-PSMA-617. Of 831 enrolled patients with PSMA-positive progressive mCRPC treated previously with one or more androgen receptor pathway inhibitors and one to two taxanes, 551 were randomised to 177 Lu-PSMA-617 plus protocol-permitted standard of care (SoC). Radiographic progression-free survival, overall survival, radiographic objective response rate, and patient-reported health-related quality of life (HRQoL) and pain were analysed in subgroups of patients categorised by the magnitude of unconfirmed PSA decline from baseline. Patients randomised to 177 Lu-PSMA-617 with the best PSA declines of ≥0–<50% (96/551 [17%]), ≥50–<90% (152/551 [28%]), and ≥90% (83/551 [15%]) up to and including week 12 had 61%, 72%, and 88% reduced risks of radiographic disease progression or death, and 51%, 70%, and 87% reduced risks of death, respectively, versus those with increased PSA levels (160/551 [29%]), based on hazard ratios in a multivariate Cox proportional hazard model. In patients with greater PSA declines, radiographic responses were more frequent and median time to worsening in HRQoL and pain scores were longer. The magnitude of PSA decline was associated with improvement in clinical and patient-reported outcomes in patients with mCRPC receiving 177 Lu-PSMA-617 plus SoC in VISION. PSA decline therefore appears to have a prognostic value during 177 Lu-PSMA-617 treatment in this population.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.015
Threshold uncertainty score0.463

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0030.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.072
GPT teacher head0.404
Teacher spread0.332 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations21
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueEuropean UrologySame topicProstate Cancer Treatment and ResearchFrench-language works237,207